DePuy Orthopaedics: The Hip on Paper and the Implant in the Patient

The DePuy false claims case over Pinnacle metal-on-metal hip implants ended in dismissal after a court allowed allegations about defective units to proceed. The surgeons who brought it alleged that DePuy supplied implants that departed from the cleared specifications, leaving hospitals to seek Medicare and Medicaid payment for devices they believed matched the cleared product. The surgeons alleged that patients faced painful failures and replacement surgery, while public health programs paid for implants allegedly made outside the cleared specifications.

Two orthopedic surgeons with experience implanting Pinnacle devices brought the qui tam case. The district court’s account describes one as a member of DePuy’s Pinnacle user group and the other as a researcher on failed hip replacements who also consulted for the Food and Drug Administration. The United States declined to join the case.

The 2017 First Circuit decision separated two allegations that can sound similar outside a device company. One challenged the information used to obtain Food and Drug Administration clearance. The other challenged whether the implants sold to healthcare providers matched the cleared specifications. The court allowed the manufacturing allegations to proceed.

The Alleged Defects Were in the Fit and the Finish

The Pinnacle allegations concerned dimensions and surface roughness in a metal-on-metal hip replacement. These were manufacturing details with consequences inside the patient.

The artificial head and cup needed room for bodily fluid to cushion their movement. The complaint alleged that some components fitted too tightly, allowing metal to rub directly against metal. A second alleged defect concerned excessive roughness at the taper-trunnion junction, where the stem connects to the head. That roughness increased friction and the shedding of metal debris.

The court described how metal debris could cause pain and a damaging soft-tissue reaction, sometimes requiring revision surgery to replace the implant. The alleged discrepancy was therefore more than a measurement on an engineering drawing. It concerned whether a hip replacement would work as intended after it was inside someone.

The opinion quoted the complaint’s manufacturing allegation:

The complaint linked the manufacturing defects to a five-year failure rate of nearly fifteen percent. The alleged difference between the specified implant and the one supplied was something a patient could end up needing another operation to discover.

Why the FDA Theory Failed

The FDA theory failed because the surgeons told the Food and Drug Administration about their design concerns, but the agency left the hip on the market. DePuy discontinued it in 2013.

The complaint also alleged that doctors heard a much more reassuring sales pitch than the agency did: a five-year failure rate of 0.1%, against 4% to 4.5% in the company’s regulatory filings. The court rejected the argument that those alleged misstatements had caused the government to pay.

The surviving manufacturing allegation took a different path. It accepted the cleared product as the benchmark and alleged that DePuy supplied something materially different. The question became what left the factory.

How a Hip Implant Becomes a Government Claim

A manufacturer can cause a false claim through the provider that buys and implants its product. That was the route the First Circuit allowed this case to pursue.

The device business splits the purchasing decision across several people. The Department of Health and Human Services Office of Inspector General’s description of implantable devices explains that a physician may choose or strongly influence the brand and type, while the hospital or surgery center buys it.

In manufacturers’ consignment arrangements, the manufacturer may still own the implant on the hospital shelf, with the sale occurring when it is used.

On the payment side, Medicare usually includes an implanted device’s cost in the procedure payment.

That makes the provider’s bill part of the manufacturer’s story. The product selection, the implant actually used and the reimbursement claim connect decisions made in different parts of the business. Food and Drug Administration authorization governs market access. Medicare coverage and payment answer separate questions about the care being billed.

The complaint supplied a concrete example. It alleged that a surgeon at Stony Brook University Medical Center implanted a Pinnacle metal-on-metal device in November 2007. The device allegedly failed because of manufacturing defects, including incorrect clearance dimensions. Unaware of the defect, the medical center allegedly submitted a Medicaid claim for the device and surgery. The hospital’s role in that account was to rely on the product it received.

The 2020 Journal of Forensic and Investigative Accounting paper, A Forensic Accountant’s Guide to the Most Potent Federal Laws Used Against Healthcare Fraud, puts the goods-and-payment connection plainly:

In the Pinnacle allegation, the product represented to the provider was a conforming implant. The product allegedly supplied had a hidden manufacturing departure. The provider then sought payment on the understanding that it had used the conforming product.

The Hidden Defect Made the Billing Connection Stronger

The alleged defects would not have become apparent during surgery, so doctors would have had no reason to withhold a reimbursement claim. That timing mattered to the court’s decision to let the manufacturing claim proceed.

The First Circuit contrasted this case with an earlier case against ev3. There, the alleged defect caused a device to fail while surgeons were trying to use it, before a reimbursement claim might have been submitted. The Pinnacle allegations described defects that remained hidden through implantation and billing. The same word, defective, described two different paths to a possible government claim.

The complaint also alleged that approximately 18,750 Pinnacle metal-on-metal devices had been sold to Medicare patients between 2005 and 2009. The court considered the alleged scale, manufacturing departures and hidden defects together in deciding that the complaint connected DePuy’s conduct to provider claims.

For New York, the complaint combined Medicaid hip-replacement claim counts with DePuy’s market share to estimate that the program had paid for nearly 425 Pinnacle devices with the clearance defect between 2005 and 2010. The court accepted that account as enough for the New York manufacturing claims to proceed. The connection to payment came from the patient example and the wider pattern of sales and coverage.

Why the DePuy Case Ended

The case ended because the surgeons used confidential information from separate patient-injury lawsuits in violation of court orders. The 2023 First Circuit opinion explains that the court dismissed the case for those violations.

What Qualifies as a Whistleblower Complaint?

A defective-implant case connects what the manufacturer knew and supplied to what health care providers used and billed. Building that connection is our work with you. The Pinnacle case shows how specific that account can become: dimensions, tolerances, the timing of a failure and the provider’s understanding of the product.

In a whistleblower case the government joined against Guidant, the government alleged that an internal committee recommended continuing to sell defective devices already in field inventory, including stock held by sales representatives, after a stop-ship order. An instruction at the factory and the inventory reaching patients could tell different stories.

That is where a quality, manufacturing or sales insider’s knowledge can matter. Specifications show what was supposed to be made. Quality analyses address what was made. Sales and implantation records connect the units to providers and patients. We work with you to establish how those records fit the government payment and the company’s decisions.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

You Know What Left the Factory

If you know where implant specifications, quality findings and sales records diverge, speak to our whistleblower experts about the implants that left the factory. We build your strongest medical device whistleblower case with you and bring in medical device fraud whistleblower lawyers who understand manufacturing evidence and provider claims. We stay beside you as the technical account becomes the case for recovering public money.